Colivelin (TFA)
Colivelin TFA is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3 in vitro[1]. Colivelin TFA exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease[2]. Colivelin TFA has the potential for the treatment of alzheimer's disease and ischemic brain injury[1].
Product Specifications
CAS Number
[2803948-60-7]
UNSPSC
12352209
Target
Amyloid-β; Apoptosis; STAT
Type
Peptides
Related Pathways
Apoptosis; JAK/STAT Signaling; Neuronal Signaling; Stem Cell/Wnt
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/Colivelin_TFA.html
Purity
99.52
Solubility
H2O : 50 mg/mL (ultrasonic)
Smiles
O=C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CO)C(N[C@@H]([C@@H](C)CC)C(N1[C@@H](CCC1)C(N[C@@H](C)C(N2[C@@H](CCC2)C(N[C@@H](C)C(NCC(N[C@@H](C)C(N[C@@H](CO)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H]([C@H](O)C)C(NCC(N[C@@H](CCC(O)=O)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(C)C)C(N3[C@@H](CCC3)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CO)N.OC(C(F)(F)F)=O
Molecular Formula
C119H206N32O35.C2HF3O2
Molecular Weight
2759.12
References & Citations
[1]Chiba T, et al. Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus: characterization of colivelin-mediated neuroprotection against Alzheimer's disease-relevant insults in vitro and in vivo. J Neurosci. 2005 Nov 2;25 (44) :10252-61.|[2]Zhao H, et al. Colivelin Rescues Ischemic Neuron and Axons Involving JAK/STAT3 Signaling Pathway.Neuroscience. 2019 Sep 15;416:198-206.|[3]Pan Z, et al. Upregulation of HSP72 attenuates tendon adhesion by regulating fibroblast proliferation and collagen production via blockade of the STAT3 signaling pathway.Cell Signal. 2020 Mar 18:109606.|[4]Fang YY, et al. MFG-E8 alleviates oxygen-glucose deprivation-induced neuronal cell apoptosis by STAT3 regulating the selective polarization of microglia. Int J Neurosci. 2020 Mar 12:1-10.|[5]Chiu WC, et al. The Synthetic β-Nitrostyrene Derivative CYT-Rx20 Inhibits Esophageal Tumor Growth and Metastasis via PI3K/AKT and STAT3 Pathways. PLoS One. 2016 Nov 22;11 (11) :e0166453.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
No Development Reported
Isoform
STAT3
Citation 01
Ann Transl Med. 2020 Nov;8 (21) :1346.|Antiviral Res. 2022 Jan:197:105228.|Biochem Cell Biol. 2022 Dec 1;100 (6) :473-484.|Biochem Cell Biol. 2023 Feb 1;101 (1) :1-11.|Biomed Pharmacother. 2020 Nov;131:110541.|Biomol Biomed. 2024 Dec 11;25 (1) :82-93.|Brain Res Bull. 2024 Nov 13:219:111128.|Burns. 2025 Jun 23;51 (8) :107586.|Cell Commun Signal. 2021 Nov 16;19 (1) :115.|Drug Resist Updat. 2025 Jul:81:101224.|Exp Ther Med. 2022 Apr;23 (4) :313.|Frigid Zone Medicine. 20 May 2022.|Front Mol Biosci. 2021 Jun 18:8:654766.|Inflamm Bowel Dis. 2023 Dec 5;29 (12) :1929-1940.|Int Immunopharmacol. 2024 May 30:133:112126.|Int Immunopharmacol. 2024 Oct 18;143 (Pt 2) :113416.|Int J Biol Sci. 2023 Apr 2;19 (7) :2021-2033.|Int J Biol Sci. 2025 Apr 28;21 (7) :3229-3246.|Int J Neurosci. 2021 Jan;131 (1) :15-24.|Iran J Basic Med Sci. 2025.|J Adv Res. 2025 Mar 31:S2090-1232 (25) 00218-8.|J Agric Food Chem. 2021 Jul 21;69 (28) :7898-7909.|J Agric Food Chem. 2025 Mar 5;73 (9) :5208-5222.|J Inflamm Res. 24 May 2022.|J Nanobiotechnology. 2024 Jun 19;22 (1) :345.|Mol Immunol. 2025 May:181:9-17.|Nat Commun. 2021 Nov 25;12 (1) :6891.|PeerJ. 2022 Sep 28;10:e14086.|Phytomedicine. 2023 Jan:109:154551.|Phytomedicine. 2023 Jun:114:154799.|Proc Natl Acad Sci U S A. 2022 Oct 11;119 (41) :e2122099119.|Research Square Preprint. 2020 Dec.|Sci Rep. 2025 Jun 5;15 (1) :19736.|SSRN. 2025 Jan 30.|Vascul Pharmacol. 2024 Jul 17:107411.|Adv Rheumatol. 2024 Dec 18;64 (1) :88.|Aging. 2020 May 15;12 (10) :9066-9084.|Biochim Biophys Acta Mol Basis Dis. 2024 Feb;1870 (2) :166979.|BMC Neurosci. 2025 Mar 7;26 (1) :21.|Cancer Immunol Immunother. 2022 Jun 20.|Cell Signal. 2020 Jul;71:109606.|Cell Signal. 2026 Feb:138:112250.|CNS Neurosci Ther. 2024 Apr;30 (4) :e14512.|Commun Biol. 2022 Dec 1;5 (1) :1316.|Drug Dev Res. 2022 Dec;83 (8) :1831-1844.|Ecotoxicol Environ Saf. 2024 Aug 12:283:116857.|Free Radic Biol Med. 2024 Aug 28:S0891-5849 (24) 00630-0.|Funct Integr Genomics. 2025 Mar 12;25 (1) :59.|Inflammation. 2025 Feb;48 (1) :372-392.|Int J Mol Sci. 2024 Mar 3;25 (5) :2950.|Int J Nanomedicine. 2023 Nov 29:18:7095-7113.|J Agric Food Chem. 2025 Oct 22;73 (42) :27025-27037.|J Ethnopharmacol. 2024 Sep 13:118829.|J Ethnopharmacol. 2025 Oct 22:120772.|J Inflamm Res. 2025 Sep 8:18:12361-12377.|J Nanobiotechnology. 2024 Aug 24;22 (1) :509.|J Nanobiotechnology. 2024 Jul 11;22 (1) :409.|J Nanobiotechnology. 2025 Mar 29;23 (1) :258.|J Nat Med. 2020 Jun;74 (3) :533-544. |J Physiol Investig. 2024 Jan 1;67 (1) :37-46.|J Surg Res. 2025 Jan 13:306:249-256.|J Transl Med. 2025 Jul 10;23 (1) :780.|J Transl Med. 2025 May 2;23 (1) :502.|J Transl Med. 2025 May 27;23 (1) :593.|J Transl Med. 2025 Oct 2;23 (1) :1043.|Mol Biol Rep. 2024 Jan 22;51 (1) :176.|Oncol Rep. 2024 May;51 (5) :71.|Phytomedicine. 2024 Jul:129:155563.|Phytomedicine. 2025 Sep 11:148:157257.|Pol J Pathol. 2025;76 (2) :131-140.|Preprints. 2025 Jun 24.|Redox Biol. 2023 Dec:68:102956.|Sci Rep. 2025 May 2;15 (1) :15378.|Sci Transl Med. 2021 Oct 6;13 (614) :eabg6428.|SSRN. 2024 Apr 7.|Stem Cell Res Ther. 2025 May 5;16 (1) :227.|Tissue Cell. 2024 Nov 30:93:102645.|World J Stem Cells. 2024 Nov 26;16 (11) :906-925.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
